Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer

被引:26
作者
Gandaglia, Giorgio [1 ,2 ]
Sun, Maxine [1 ]
Huc, Jim C. [3 ]
Novara, Giacomo [4 ]
Choueiri, Toni K. [5 ]
Nguyen, Paul L. [6 ]
Schiffmann, Jonas [1 ]
Graefen, Markus [7 ]
Shariat, Shahrokh F. [8 ]
Abdollah, Firas [2 ]
Briganti, Alberto [2 ]
Montorsi, Francesco [2 ]
Quoc-Dien Trinh [9 ]
Karakiewicz, Pierre I. [1 ]
机构
[1] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ H2X 3J4, Canada
[2] Univ Vita Salute San Raffaele, Urol Res Inst, Milan, Italy
[3] Calif State Univ Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90032 USA
[4] Univ Padua, Dept Surg Oncol & Gastroenterol, Urol Clin, Padua, Italy
[5] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol,Div Urol,Med Sch, Boston, MA 02115 USA
[7] Univ Hosp Hamburg Eppendorf, Martini Klin, Hamburg, Germany
[8] Med Univ Vienna, Dept Urol, Vienna, Austria
[9] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Surg,Div Urol,Med Sch, Boston, MA 02115 USA
关键词
Androgen deprivation therapy; Prostate cancer; Side effects; Renal failure; Competing risks; Acute kidney injury; ANDROGEN-DEPRIVATION THERAPY; ACUTE-RENAL-FAILURE; CARDIOVASCULAR-DISEASE; MEN; RISK; MORTALITY; CARCINOMA; GNRH;
D O I
10.1016/j.eururo.2014.01.026
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Androgen deprivation therapy (ADT) might increase the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). Objective: To examine the impact of ADT on AKI in a large contemporary cohort of patients with nonmetastatic PCa representing the US population. Design, setting, and participants: Overall, 69 292 patients diagnosed with nonmetastatic PCa between 1995 and 2009 were abstracted from the Surveillance Epidemiology and End Results-Medicare database. Outcomes measurements and statistical analyses: Patient in both treatment arms (ADT vs no ADT) were matched using propensity-score methodology. Ten-year AKI rates were estimated. Competing-risks regression analyses tested the association between ADT and AKI, after adjusting for the risk of death during follow-up. Results and limitations: Overall, the 10-yr AKI rates were 24.9% versus 30.7% for ADT-naive patients versus those treated with ADT, respectively (p < 0.001). When patients were stratified according to the type of ADT, the 10-yr AKI rates were 31.1% versus 26.0% for men treated with gonadotropin-releasing hormone (GnRH) agonists and bilateral orchiectomy, respectively (p < 0.001). In multivariable analyses, the administration of GnRH agonists (hazard ratio [HR]: 1.24; 95% confidence interval [CI], 1.18-1.31; p < 0.001), but not bilateral orchiectomy (HR: 1.11; 95% CI, 0.96-1.29; p = 0.1), was associated with the risk of experiencing AKI. Our study is limited by its retrospective design. Conclusions: ADT is associated with an increased risk of AKI in patients with nonmetastatic PCa. In particular, the administration of GnRH agonists, but not surgical castration, may substantially increase the risk of experiencing AKI. These observations should help provide physicians with better patient selection to reduce the risk of AKI. Patient summary: The administration of gonadotropin-releasing hormone agonists, but not bilateral orchiectomy, increases the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). These observations should help provide physicians with better patient selection to reduce the risk of AKI in PCa patients. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1125 / 1132
页数:8
相关论文
共 50 条
  • [21] Oncological Outcomes of Hormonal Therapy with a Gonadotropin-releasing Hormone Agonist Combined with a Steroidal or Non-Steroidal Antiandrogen in Patients with Prostate Cancer
    Igawa, Tsukasa
    Tsurusaki, Toshifumi
    Nomata, Koichiro
    Hayashi, Mikio
    Furukawa, Masataka
    Sakai, Hideki
    ANTICANCER RESEARCH, 2014, 34 (04) : 1983 - 1988
  • [22] Reproduction and longevity: A Mendelian randomization study of gonadotropin-releasing hormone and ischemic heart disease
    Schooling, C. M.
    Ng, Jack C. M.
    SSM-POPULATION HEALTH, 2019, 8
  • [23] Body Composition and Markers of Cardiometabolic Health in Transgender Youth on Gonadotropin-Releasing Hormone Agonists
    Nokoff, Natalie J.
    Scarbro, Sharon L.
    Moreau, Kerrie L.
    Zeitler, Philip
    Nadeau, Kristen J.
    Reirden, Daniel
    Juarez-Colunga, Elizabeth
    Kelsey, Megan M.
    TRANSGENDER HEALTH, 2021, 6 (02) : 111 - 119
  • [24] Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
    Liu, Yi-Fu
    Fu, Sheng-Qiang
    Yan, Yu-Chang
    Gong, Bin-Bin
    Xie, Wen-Jie
    Yang, Xiao-Rong
    Sun, Ting
    Ma, Ming
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 639 - 649
  • [25] Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura, Takahiro
    Sasaki, Hiroshi
    Akazawa, Kouhei
    Egawa, Shin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (07) : 322 - 328
  • [26] Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials
    Abufaraj, Mohammad
    Iwata, Takehiro
    Kimura, Shoji
    Haddad, Anoud
    Al-Ani, Hashim
    Abusubaih, Lana
    Moschini, Marco
    Briganti, Alberto
    Karakiewicz, Pierre I.
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2021, 79 (01) : 44 - 53
  • [27] Testosterone Recovery after Neoadjuvant Gonadotropin-Releasing Hormone Antagonist versus Agonist on Permanent Iodine-125 Seed Brachytherapy in Prostate Cancer Patients: A Propensity Score Analysis
    Iwata, Takehiro
    Maruyama, Yuki
    Kawada, Tatsushi
    Sadahira, Takuya
    Katayama, Satoshi
    Takamoto, Atsushi
    Sako, Tomoko
    Wada, Koichiro
    Edamura, Kohei
    Kobayashi, Yasuyuki
    Araki, Motoo
    Watanabe, Masami
    Watanabe, Toyohiko
    Nasu, Yasutomo
    ACTA MEDICA OKAYAMA, 2021, 75 (06) : 705 - 711
  • [28] A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
    Miyazawa, Yoshiyuki
    Sekine, Yoshitaka
    Syuto, Takahiro
    Nomura, Masashi
    Koike, Hidekazu
    Matsui, Hiroshi
    Shibata, Yasuhiro
    Ito, Kazuto
    Suzuki, Kazuhiro
    BMC UROLOGY, 2017, 17
  • [29] Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostrate Cancer
    Saylor, Philip J.
    Keating, Nancy L.
    Freedland, Stephen J.
    Smith, Matthew R.
    DRUGS, 2011, 71 (03) : 255 - 261
  • [30] Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer
    Beckmann, Kerri
    Garmo, Hans
    Adolfsson, Jan
    Bosco, Cecilia
    Johansson, Eva
    Robinson, David
    Holmberg, Lars
    Stattin, Par
    Van Hemelrijck, Mieke
    EUROPEAN UROLOGY, 2019, 75 (04) : 676 - 683